Last reviewed · How we verify
IBI110 plus sintilimab — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
IBI110 plus sintilimab (IBI110 plus sintilimab) — Innovent Biologics (Suzhou) Co. Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| IBI110 plus sintilimab TARGET | IBI110 plus sintilimab | Innovent Biologics (Suzhou) Co. Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- IBI110 plus sintilimab CI watch — RSS
- IBI110 plus sintilimab CI watch — Atom
- IBI110 plus sintilimab CI watch — JSON
- IBI110 plus sintilimab alone — RSS
Cite this brief
Drug Landscape (2026). IBI110 plus sintilimab — Competitive Intelligence Brief. https://druglandscape.com/ci/ibi110-plus-sintilimab. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab